Pfizer has begun phase 1 US clinical trials of the candidates PF-07321332 (oral administration) and PF-07304814 (intravenous administration) in hospitalized participants with COVID-19. Both drugs work by inhibiting an enzyme that the SARS-CoV-2 virus needs to replicate in human cells.
Early-stage clinical trial for oral COVID-19 drug
